DOM-LEVETIRACETAM 250 MG — DIN 02297396
LEVETIRACETAM : 250 MG · DOMINION PHARMACAL · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is DOM-LEVETIRACETAM?
DOM-LEVETIRACETAM 250 MG contains LEVETIRACETAM : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02297396, held by DOMINION PHARMACAL, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 09-May-2025. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is DOM-LEVETIRACETAM used for?
Adjunctive therapy in the management of adult patients with epilepsy who are not satisfactorily controlled by conventional therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Levetiracetam cost around the world?
Levetiracetam is listed on 19 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| Brazil | preco fabrica (ex-factory ceiling) | 17 | 192 |
| Spain | PVP con IVA (public price) | 135 | 146 |
| United States | acquisition | 5 | 119 |
| Italy | prezzo al pubblico (classe A) | 39 | 73 |
| Saudi Arabia | public | 47 | 70 |
| Australia | ex-manufacturer | 13 | 60 |
| Austria | KVP (Kassenverkaufspreis) | 31 | 59 |
| Czechia | max producer price (ex-factory) | 14 | 53 |
| United Arab Emirates | public | 39 | 47 |
| Greece | producer price (ex-factory) | 30 | 30 |
| South Africa | single exit price | 27 | 27 |
| Bahrain | retail (max) | 11 | 26 |
| Norway | max AUP (pharmacy retail) | 5 | 26 |
| Slovakia | categorised final price | 21 | 22 |
| Hungary | producer price (ex-factory) | 18 | 20 |
| Romania | max producer price | 12 | 15 |
| United Kingdom | hospital | 11 | 11 |
| Luxembourg | reimbursement | 6 | 6 |
| Morocco | PPV (public price) | 3 | 5 |
1007 pack listings across 484 brand entries and 17 price bases, refreshed 10 Sep 2026. Ranges span every Levetiracetam pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Levetiracetam in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
33 holders have a Canadian DIN containing Levetiracetam, across 109 DINs, of which 47 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PHARMASCIENCE INC | 8 | 4 | LEVETIRACETAM, PHARMA-LEVETIRACETAM, PMS-LEVETIRACETAM | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 4 | 4 | MINT-LEVETIRACETAM, MINT-LEVETIRACETAM SOLUTION | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 4 | 4 | SANDOZ LEVETIRACETAM | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 6 | 3 | JAMP LEVETIRACETAM TABLETS, JAMP-LEVETIRACETAM | Sourceable in Canada |
| TEVA CANADA LIMITED | 6 | 3 | TEVA-LEVETIRACETAM, TVA-LEVETIRACETAM | Sourceable in Canada |
| SANIS HEALTH INC | 4 | 3 | LEVETIRACETAM | Sourceable in Canada |
| ACCORD HEALTHCARE INC | 3 | 3 | ACH-LEVETIRACETAM | Sourceable in Canada |
| ANGITA PHARMA INC. | 3 | 3 | AG-LEVETIRACETAM | Sourceable in Canada |
| APOTEX INC | 3 | 3 | APO-LEVETIRACETAM | Sourceable in Canada |
| AURO PHARMA INC | 3 | 3 | AURO-LEVETIRACETAM | Sourceable in Canada |
| PRO DOC LIMITEE | 3 | 3 | PRO-LEVETIRACETAM - 250, PRO-LEVETIRACETAM - 500, PRO-LEVETIRACETAM - 750 | Sourceable in Canada |
| SIVEM PHARMACEUTICALS ULC | 3 | 3 | LEVETIRACETAM | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 250 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in provided text (Summary section mentions 250 mg, 500 mg, and 750 mg strengths). |
| Storage | Not specified in the provided text (refer to STORAGE AND STABILITY section on page 19, which is not included in the snippet). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Levetiracetam |
|---|---|
| ATC code | N03AX14 |
| AHFS class | 28:12.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02297396 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2297396 |
| Brand name | DOM-LEVETIRACETAM |
| Generic / active ingredient | LEVETIRACETAM : 250 MG |
| Market authorization holder | DOMINION PHARMACAL |
| Health Canada schedule | Prescription |
| ATC code | N03AX14 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N03AX |
| Current status | CANCELLED POST MARKET |
| Status date | 09-May-2025 |
| Original market date | 2008-04-16 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: Initial dose 500 mg BID; may increase by 1000 mg/day every 2 weeks to max 3000 mg/day. Adjust dose in renal impairment. Withdraw gradually.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to levetiracetam, other ingredients in the formulation, or component of the container.
Warnings and precautions
CNS effects (somnolence, fatigue, coordination difficulties); Suicidal ideation/behavior; Serious skin reactions (SJS, TEN, DRESS); Anaphylaxis/angioedema; Hematologic abnormalities.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
47 of 109 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-LEVETIRACETAM | 750 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02399792 |
| ACH-LEVETIRACETAM | 500 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02399784 |
| ACH-LEVETIRACETAM | 250 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02399776 |
| AG-LEVETIRACETAM | 750 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02485214 |
| AG-LEVETIRACETAM | 250 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02485192 |
| AG-LEVETIRACETAM | 500 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02485206 |
| APO-LEVETIRACETAM | 250 MG | TABLET | APOTEX INC | MARKETED | 02285924 |
| APO-LEVETIRACETAM | 750 MG | TABLET | APOTEX INC | MARKETED | 02285940 |
| APO-LEVETIRACETAM | 500 MG | TABLET | APOTEX INC | MARKETED | 02285932 |
| AURO-LEVETIRACETAM | 750 MG | TABLET | AURO PHARMA INC | MARKETED | 02375265 |
2 · Same class — other molecules in ATC N03AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Levetiracetam | ABBOTT-LEVETIRACETAM · ACH-LEVETIRACETAM · AG-LEVETIRACETAM · APO-LEVETIRACETAM · +31 more | 109 | 47 | Yes |
| Topiramate | ABBOTT-TOPIRAMATE · ACCEL-TOPIRAMATE · ACH-TOPIRAMATE · AG-TOPIRAMATE · +32 more | 125 | 42 | Yes |
| Lacosamide | ACH-LACOSAMIDE · AG-LACOSAMIDE · ALEMBIC-LACOSAMIDE · APO-LACOSAMIDE · +12 more | 66 | 41 | Yes |
| Lamotrigine | AG-LAMOTRIGINE · APO-LAMOTRIGINE · AURO-LAMOTRIGINE · DOM-LAMOTRIGINE · +13 more | 48 | 29 | Yes |
| Brivaracetam | APO-BRIVARACETAM · AURO-BRIVARACETAM · BRIVLERA | 14 | 14 | Yes |
| Perampanel | FYCOMPA · TARO-PERAMPANEL | 13 | 12 | Yes |
| Cenobamate | XCOPRI | 11 | 8 | Yes |
| Stiripentol | DIACOMIT | 4 | 3 | Yes |
| Cannabidiol | EPIDIOLEX | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N03AF | Carbamazepine · Eslicarbazepine · Oxcarbazepine · Rufinamide | 86 | 33 |
| N03AG | Valproic Acid · Vigabatrin | 75 | 19 |
| N03AA | Phenobarbital · Primidone | 39 | 13 |
| N03AB | Fosphenytoin · Phenytoin · Phenytoin, Combinations | 17 | 8 |
| N03AE | Clonazepam | 55 | 8 |
| N03AD | Ethosuximide · Mesuximide | 5 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DOM-LEVETIRACETAM called?
The same molecule, Levetiracetam, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| LEVETIRACETAM | Latin | Brazil |
| Keppra | Latin | Australia, Bahrain, Brazil, Czechia, Morocco, Norway, Saudi Arabia |
| VEEPI | Latin | Brazil |
| APO-Levetiracetam | Latin | Australia |
| Levetiracetam Accord | Latin | Czechia, Norway |
| Levetiracetam GH | Latin | Australia |
| Antagra | Latin | Bahrain, Saudi Arabia |
| ILUDRAL | Latin | Brazil |
| Levactam | Latin | Australia |
| Levetiracetam SZ | Latin | Australia |
| Levetiracetam Viatris | Latin | Australia |
| LEVETIRACETAM-WGR | Latin | Australia |
| ANTARA | Latin | Brazil |
| DRETACEN | Latin | Czechia |
| EPILETAM | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
What is Levetiracetam called in other languages?
Buyers, prescribers and procurement teams outside Canada often search for the ingredient in their own script. These are phonetic renderings of the ingredient name Levetiracetam, published to help those searches reach this page.
| Language | Levetiracetam |
|---|---|
| Arabic العربية | ليفيتيراسيتام |
| Chinese (Simplified) 简体中文 | 左乙拉西坦 |
| Russian Русский | леветирацетам |
| Spanish Español | levetiracetam |
| French Français | lévétiracétam |
| Portuguese Português | levetiracetam |
| German Deutsch | Levetiracetam |
| Japanese 日本語 | レベチラセタム |
These are transliterations of the ingredient name, generated automatically and published only where two independent checks agreed. They are not registered local trade names and carry no marketing authorisation in any market. Always confirm a product against its local registration before ordering.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.